BRPI0413758A - compostos para o tratamento de transtornos metabólicos - Google Patents
compostos para o tratamento de transtornos metabólicosInfo
- Publication number
- BRPI0413758A BRPI0413758A BRPI0413758-2A BRPI0413758A BRPI0413758A BR PI0413758 A BRPI0413758 A BR PI0413758A BR PI0413758 A BRPI0413758 A BR PI0413758A BR PI0413758 A BRPI0413758 A BR PI0413758A
- Authority
- BR
- Brazil
- Prior art keywords
- carbon atoms
- hydrogen
- alkyl
- ring
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000030159 metabolic disease Diseases 0.000 title abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 206010006895 Cachexia Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- -1 perfluoromethoxy Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"COMPOSTOS PARA O TRATAMENTO E TRANSTORNOS METABóLICOS". São revelados agentes úteis para o tratamento de vários transtornos metabólicos, tais como síndrome de resistência à insulina, diabetes, hiperlipidemia, doença do fígado obeso, cachexia, obesidade, aterosclerose e arteriosclerose. Fórmula (I), na qual n é 1 ou 2; m é 0 ou 1; q é 0 ou 1; t é 0 ou 1; R¬ 5¬ é alquila tendo de 1 a 3 átomos de carbono; R¬ 9¬ é hidrogênio, halo, alquila tendo de 1 a 3 átomos de carbono ou alcóxi tendo de 1 a 3 átomos de carbono; A é fenila, não substituída ou substituída por 1 ou 2 grupos selecionados de: halo, alquila tendo 1 ou 2 átomos de carbono, perfluormetila, alcóxi tendo 1 ou 2 átomos de carbono e perfluormetóxi; ou cicloalquila tendo de 3 à 6 átomos de carbono no anel na qual a cicloalquila é não substituída ou um ou dois carbonos no anel são independentemente mono-substituídos por metila ou etila, ou um anel heteroaromático de 5 ou 6 membros tendo 1 ou 2 heteroátomos selecionados de N, S e O e o anel heteroaromático é covalentemente ligado ao restante do composto de fórmula I por um carbono do anel; e X é -CH~ 2~-, Q é -OR¬ 1¬ e R¬ 1¬ é metila ou etila; ou X é -CH~ 2~CR¬ 12¬R¬ 13¬ ou -CH~ 2~CH(NHAc)- na qual cada um de R¬ 12 e R¬ 13¬ é independentemente hidrogênio ou metila, Q é OR¬ 1¬ e R¬ 1¬ é hidrogênio ou alquila tendo de 1 a 7 átomos de carbono ou X é -CH~ 2~CH~ 2~- e Q é NR¬ 10¬R¬ 11¬ na qual um de R¬ 10¬ e R¬ 11¬ é hidrogênio, alquila tendo de 1 a 3 átomos de carbono ou hidróxi e o outro é hidrogênio. Alternativamente, quando R¬ 1¬ for hidrogênio, o agente biologicamente ativo pode ser um sal farmaceuticamente aceitável do composto de fórmula 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49653303P | 2003-08-20 | 2003-08-20 | |
| PCT/US2004/026561 WO2005018628A1 (en) | 2003-08-20 | 2004-08-16 | Compounds for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413758A true BRPI0413758A (pt) | 2006-10-31 |
Family
ID=34216015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413758-2A BRPI0413758A (pt) | 2003-08-20 | 2004-08-16 | compostos para o tratamento de transtornos metabólicos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7906675B2 (pt) |
| EP (1) | EP1656127B1 (pt) |
| JP (1) | JP4703563B2 (pt) |
| KR (1) | KR101069276B1 (pt) |
| CN (2) | CN101948416A (pt) |
| AT (1) | ATE502631T1 (pt) |
| AU (1) | AU2004266673B2 (pt) |
| BR (1) | BRPI0413758A (pt) |
| CA (1) | CA2533890A1 (pt) |
| DE (1) | DE602004031954D1 (pt) |
| IL (1) | IL173377A (pt) |
| MX (1) | MXPA06001963A (pt) |
| NO (1) | NO20060502L (pt) |
| NZ (1) | NZ545268A (pt) |
| RU (1) | RU2349584C2 (pt) |
| UA (1) | UA88772C2 (pt) |
| WO (1) | WO2005018628A1 (pt) |
| ZA (1) | ZA200600577B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1750758B (zh) * | 2003-02-13 | 2012-06-20 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| RU2358722C2 (ru) * | 2003-04-15 | 2009-06-20 | Веллстат Терапьютикс Корпорейшн | Соединения для лечения метаболических расстройств |
| JP4837557B2 (ja) * | 2003-04-30 | 2011-12-14 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
| CA2602854C (en) * | 2005-04-01 | 2013-05-14 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| UA95613C2 (ru) * | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
| NZ569728A (en) * | 2006-01-25 | 2010-11-26 | Wellstat Therapeutics Corp | Compounds for the treatment of metabolic disorders |
| JP2009528275A (ja) * | 2006-01-25 | 2009-08-06 | ウェルスタット セラピューティクス コーポレイション | 代謝障害を処置するための化合物 |
| WO2007087505A2 (en) * | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US20090176885A1 (en) * | 2006-02-02 | 2009-07-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| EP1983972A4 (en) * | 2006-02-13 | 2012-01-25 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| KR20080098615A (ko) * | 2006-02-28 | 2008-11-11 | 웰스태트 테러퓨틱스 코포레이션 | 물질대사 장애의 치료용 화합물 |
| KR20080106455A (ko) * | 2006-03-31 | 2008-12-05 | 웰스태트 테러퓨틱스 코포레이션 | 대사장애의 조합치료 |
| CA2651598A1 (en) * | 2006-05-18 | 2007-11-29 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| EP2026659A4 (en) * | 2006-06-09 | 2010-06-30 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER |
| EP2240024A4 (en) * | 2008-01-15 | 2014-05-21 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| CN109096350B (zh) * | 2017-09-21 | 2020-07-28 | 暨南大学 | 辣木籽中新的硫醚类化合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5035M (pt) | 1964-07-28 | 1967-05-02 | ||
| CA2283642C (en) * | 1997-03-17 | 2012-05-15 | Btg International Limited | Therapeutic compositions |
| CN101444496B (zh) | 2001-06-12 | 2011-04-13 | 维尔斯达医疗公司 | 用于治疗代谢失调的化合物 |
| EP1556085A4 (en) | 2002-11-01 | 2012-08-22 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLISM |
| CN1750758B (zh) | 2003-02-13 | 2012-06-20 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| RU2358722C2 (ru) | 2003-04-15 | 2009-06-20 | Веллстат Терапьютикс Корпорейшн | Соединения для лечения метаболических расстройств |
| US7361686B2 (en) | 2003-04-22 | 2008-04-22 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| JP4837557B2 (ja) | 2003-04-30 | 2011-12-14 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
-
2004
- 2004-08-16 EP EP04781277A patent/EP1656127B1/en not_active Expired - Lifetime
- 2004-08-16 AT AT04781277T patent/ATE502631T1/de not_active IP Right Cessation
- 2004-08-16 KR KR1020067003221A patent/KR101069276B1/ko not_active Expired - Fee Related
- 2004-08-16 UA UAA200602860A patent/UA88772C2/ru unknown
- 2004-08-16 WO PCT/US2004/026561 patent/WO2005018628A1/en not_active Ceased
- 2004-08-16 CA CA002533890A patent/CA2533890A1/en not_active Abandoned
- 2004-08-16 CN CN2010102937097A patent/CN101948416A/zh active Pending
- 2004-08-16 MX MXPA06001963A patent/MXPA06001963A/es active IP Right Grant
- 2004-08-16 RU RU2006108572/04A patent/RU2349584C2/ru not_active IP Right Cessation
- 2004-08-16 NZ NZ545268A patent/NZ545268A/en unknown
- 2004-08-16 AU AU2004266673A patent/AU2004266673B2/en not_active Ceased
- 2004-08-16 US US10/566,302 patent/US7906675B2/en active Active
- 2004-08-16 DE DE602004031954T patent/DE602004031954D1/de not_active Expired - Lifetime
- 2004-08-16 CN CNA2004800235529A patent/CN1835743A/zh active Pending
- 2004-08-16 BR BRPI0413758-2A patent/BRPI0413758A/pt not_active IP Right Cessation
- 2004-08-16 JP JP2006523964A patent/JP4703563B2/ja not_active Expired - Fee Related
-
2006
- 2006-01-23 ZA ZA200600577A patent/ZA200600577B/en unknown
- 2006-01-26 IL IL173377A patent/IL173377A/en not_active IP Right Cessation
- 2006-01-31 NO NO20060502A patent/NO20060502L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007502824A (ja) | 2007-02-15 |
| KR20060066730A (ko) | 2006-06-16 |
| IL173377A0 (en) | 2006-06-11 |
| US7906675B2 (en) | 2011-03-15 |
| WO2005018628A1 (en) | 2005-03-03 |
| RU2349584C2 (ru) | 2009-03-20 |
| MXPA06001963A (es) | 2006-05-31 |
| ZA200600577B (en) | 2007-01-31 |
| DE602004031954D1 (de) | 2011-05-05 |
| EP1656127B1 (en) | 2011-03-23 |
| AU2004266673B2 (en) | 2010-08-05 |
| AU2004266673A1 (en) | 2005-03-03 |
| NZ545268A (en) | 2009-05-31 |
| HK1087040A1 (en) | 2006-10-06 |
| EP1656127A1 (en) | 2006-05-17 |
| CN1835743A (zh) | 2006-09-20 |
| CN101948416A (zh) | 2011-01-19 |
| NO20060502L (no) | 2006-05-03 |
| UA88772C2 (ru) | 2009-11-25 |
| CA2533890A1 (en) | 2005-03-03 |
| IL173377A (en) | 2012-12-31 |
| RU2006108572A (ru) | 2006-07-27 |
| ATE502631T1 (de) | 2011-04-15 |
| JP4703563B2 (ja) | 2011-06-15 |
| KR101069276B1 (ko) | 2011-10-04 |
| EP1656127A4 (en) | 2009-04-29 |
| US20070282003A1 (en) | 2007-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0407506A (pt) | compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos | |
| BRPI0413758A (pt) | compostos para o tratamento de transtornos metabólicos | |
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| ATE530066T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| UA95613C2 (ru) | Соединения для лечения расстройсв метаболизма | |
| WO2007137008A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007087505A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007095462A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2004098496A3 (en) | Compounds for the treatment of metabolic disorders | |
| BR9910371A (pt) | Composto, composição farmacêutica, agente para controlar os receptores relacionados com a retinóide, processos de prevenção e terapia da diabetes mellitus, de prevenção e terapia da hiperlipemia, para acentuar uma sensibilidade à insulina, para melhorar uma resistência à insulina, de prevenção e terapia da tolerância à glicose prejudicada, de prevenção e terapia de uma doença inflamatória, de prevenção de uma esclerose arterial, e, uso do composto | |
| WO2004093806A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007087506A3 (en) | Compounds for the treatment of metabolic disorders | |
| JP2008512408A5 (pt) | ||
| MY135954A (en) | Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid | |
| EP2269694A3 (en) | Antituberculous composition comprising oxazole compounds | |
| WO2007087504A3 (en) | Compounds for the treatment of metabolic disorders | |
| EP1868595A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER | |
| WO2007092729A3 (en) | Compounds for the treatment of metabolic disorders | |
| RU2005124286A (ru) | Производное олигосахаридов | |
| HK1103083A1 (en) | Anti-inflammatory agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: A61K 31/19, A61K 31/235, C07C 323/00, A61P 3/00, A61P 7/00 Ipc: A61K 31/19 (2011.01), A61K 31/235 (2011.01), C07C |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2320 DE 23-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |